Tectonic Therapeutic to Attend Key Investor Conferences
Tectonic Therapeutic to Attend Key Investor Conferences
Tectonic Therapeutic, Inc. (NASDAQ: TECX), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), has announced that company management will present at significant investor events.
Wells Fargo Healthcare Conference
Tectonic will participate in the 2024 Wells Fargo Healthcare Conference, providing an opportunity for the management to discuss the company's advancements and strategies.
Conference Details
Date: September 4-6, 2024
Time: 3:45 PM ET
Presenter: Alise Reicin, MD, President, CEO and Director, Tectonic Therapeutic
Format: Fireside Chat
Morgan Stanley Global Healthcare Conference
The company will also engage in the Morgan Stanley 22nd Annual Global Healthcare Conference, offering one-on-one meetings with potential investors.
Conference Details
Date: September 6, 2024
Format: Investor one-on-one meetings
Live Webcast Access
Investors can access a live webcast of the fireside chat from the Wells Fargo Healthcare Conference on the Tectonic website's Investors section. A replay will be available for approximately 90 days following the event.
About Tectonic
Tectonic Therapeutic focuses on developing biologic medicines targeting GPCRs, leveraging its proprietary GEODe™ technology platform. This innovative approach aims to tackle challenges in drug discovery and provide solutions for diseases with significant unmet medical needs. The company’s lead product candidate, TX000045 (TX45), is a unique Fc-relaxin fusion protein currently in a Phase 2 clinical trial targeting patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction, addressing a critical need in the medical community. Tectonic strives to improve patient quality of life and extend longevity through its pioneering therapies.
Company Contacts
Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com (617) 430-7576
Media: Karen Sharma, CG Life, ksharma@cglife.com (617) 571-2733
Frequently Asked Questions
What is Tectonic Therapeutic focused on?
Tectonic Therapeutic is focused on the discovery and development of therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs).
Which conferences will Tectonic attend?
Tectonic will attend the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference.
Who is presenting at the Wells Fargo Conference?
Alise Reicin, MD, the President and CEO of Tectonic Therapeutic, will present at the Wells Fargo Conference.
What is TX000045 (TX45)?
TX000045 (TX45) is Tectonic’s lead product candidate, an Fc-relaxin fusion protein aimed at treating Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction.
How can investors access the webcast?
Investors can access the live webcast on the Tectonic website under the Investors section, with a replay available for 90 days.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.